aTyr Pharma Inc (NASDAQ: ATYR) is a clinical-stage biopharmaceutical company developing therapies for rare and severe diseases, with its lead program focused on efzofitimod for pulmonary sarcoidosis and systemic sclerosis-associated interstitial lung disease (SSc-ILD). The company generates no product revenue, funding operations through equity offerings including at-the-market programs and underwritten follow-on offerings, as disclosed in its 10-K filed March 5, 2026. aTyr has reported net losses across fiscal years 2023, 2024, and 2025. Clinical trial administration is outsourced to contract research organizations (CROs) and manufacturing of clinical trial materials to contract development and manufacturing organizations (CDMOs). The company estimates a $2 to $5 billion market opportunity in pulmonary sarcoidosis and SSc-ILD based on independent consultant analyses. aTyr has sponsored clinical trials in foreign jurisdictions including Europe and Japan, the latter through a collaboration with Kyorin.

Revenue model

aTyr Pharma has no product revenue. The company funds operations through equity capital raises, including at-the-market offerings and underwritten follow-on offerings, as reported in filings through the fiscal year ended December 31, 2025.

Products and services

Lead product candidate: efzofitimod, in clinical development for pulmonary sarcoidosis and SSc-ILD. Additional candidates are in preclinical development. Clinical trial materials are manufactured by CDMOs; clinical trial administration is managed through CROs.

Customers and end markets

No commercial customers as of the fiscal year ended December 31, 2025. Target end markets are patients with rare pulmonary and fibrotic diseases, specifically pulmonary sarcoidosis and SSc-ILD. The company estimates a $2 to $5 billion addressable market opportunity in these indications.

Value-chain role

Clinical-stage drug developer. aTyr outsources clinical trial administration to CROs and clinical trial manufacturing to CDMOs. The company carries product liability insurance of $10.0 million per occurrence and up to $10.0 million in aggregate for clinical trials.

Geographic exposure

Primary operations in the United States. Clinical trials sponsored in Europe and Japan, the latter through Kyorin. Subject to EU GDPR, UK GDPR, Brazil LGPD, China PIPL, and Japan data privacy laws in connection with international clinical trial activity.

Source: SEC 10-K, filed 2026-03-05

Industry: Biological Products, (No Diagnostic Substances) Peers: Assembly Biosciences Inc GELESIS HOLDINGS, INC. Surrozen Inc Fortress Biotech Inc Cue Biopharma, Inc. /entities/fnchq HOOKIPA Pharma Inc Palvella Therapeutics Inc Xilio Therapeutics Inc